Online inquiry

IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11925MR)

This product GTTS-WQ11925MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets GUCY2C gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_004963.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2984
UniProt ID P25092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ11925MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14392MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ4954MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ11193MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI0562
GTTS-WQ15832MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ11779MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MK-3222
GTTS-WQ6728MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DS 1024
GTTS-WQ4727MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BOS161721
GTTS-WQ15300MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA TNFR55-Ig1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW